Clinical Trial Update: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

View source ↗

Summary

An observational study update assessing first-line erlotinib (Tarceva) in advanced EGFR mutation-positive non-small cell lung cancer (GERTAC); the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Status: COMPLETED